Research Article
Immunohistochemical Study of NR2C2, BTG2, TBX19, and CDK2 Expression in 31 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas
Table 3
The paired recurrent group.
| | | Recurrence | | |
| Primary | | Low- | High- | X2 | P |
| NR2C2 | Low- | 1(14.3%) | 6(85.7%) | 4.167 | 0.031 | | High- | 0(0%) | 24(100%) | | | BTG2 | Low- | 31 | 0 | - | - | | High- | 0 | 0 | | | CDK2 | Low- | 7(77.8%) | 2(22.2%) | - | 1.000 | | High- | 1(4.5%) | 21(95.5%) | | | TBX19 | Low- | 20(71.4%) | 8(28.6%) | 2.500 | 0.109 | | High- | 2(66.7%) | 1(33.3%) | | |
|
|